Skip to main content
Clinical Trials/DRKS00016987
DRKS00016987
Recruiting
Not Applicable

Evaluation of organ and tumour perfusion by contrast-enhanced ultrasound after transarterial chemoembolization because hepatocellular carcinoma

niversitätsklinikum FrankfurtMedizinische Klinik 10 sites174 target enrollmentAugust 23, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
C22.0
Sponsor
niversitätsklinikum FrankfurtMedizinische Klinik 1
Enrollment
174
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 23, 2019
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
niversitätsklinikum FrankfurtMedizinische Klinik 1

Eligibility Criteria

Inclusion Criteria

  • HCC under Treatment with TACE; Age over 18 years; informed consent.

Exclusion Criteria

  • Pregnancy, breast feeding; suspicion of allergy to Sonovue®; heart insufficiency NYHA III\-IV; acute coronary syndrome or unstable Angina pectoris in the last 7 days; cardiac dysrhythmia; acute heart failure; pulmonary Hypertension (PAP\> 90mmHg); cardiac Shunts; high blood pressure; dyspnea.

Outcomes

Primary Outcomes

Not specified

Similar Trials